Stocks to Watch: Five Below, ProAssurance, Akebia Therapeutics

Dow Jones03-19

By Connor Hart

Five Below issued an upbeat outlook for its current fiscal year ahead as it posted a narrower-than-expected decline in comparable sales during its fiscal fourth quarter. The low-cost retailer's mid-2024 reset resulted in a better-than-expected end to the year, and momentum is expected to continue into its fiscal 2025. Same-store sales fell 3.0% in its recent quarter, better than the 3.3% decline expected by Wall Street. Shares rise 9.6%, to $82.88, in after-hours trading.

ProAssurance inked a roughly $1.3 billion deal to be bought by The Doctors Co. Under the agreement, ProAssurance's stockholders would receive $25 a share in cash, representing a roughly 60% premium to Wednesday's closing price. The deal is expected to close in the first half of 2026, pending approval by the specialty insurer's shareholders. Shares surge 51%, to $23.40, in post-market trading.

Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its common stock it expects to sell, nor did it disclose anticipated proceeds. It said all shares are being offered by the company. Shares fall 21%, to $2.25, in after-hours trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 19, 2025 19:11 ET (23:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520115522?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-20 07:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520115522","market":"fut","top_or_hot":-1,"title":"Stocks to Watch: Five Below, ProAssurance, Akebia Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/FIVE\">Five Below</a> issued an upbeat outlook for its current fiscal year ahead as it posted a narrower-than-expected decline in comparable sales during its fiscal fourth quarter. The low-cost retailer's mid-2024 reset resulted in a better-than-expected end to the year, and momentum is expected to continue into its fiscal 2025. Same-store sales fell 3.0% in its recent quarter, better than the 3.3% decline expected by Wall Street. Shares rise 9.6%, to $82.88, in after-hours trading. \n</p>\n<p>\n  ProAssurance inked a roughly $1.3 billion deal to be bought by The Doctors Co. Under the agreement, ProAssurance's stockholders would receive $25 a share in cash, representing a roughly 60% premium to Wednesday's closing price. The deal is expected to close in the first half of 2026, pending approval by the specialty insurer's shareholders. Shares surge 51%, to $23.40, in post-market trading. \n</p>\n<p>\n  Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its common stock it expects to sell, nor did it disclose anticipated proceeds. It said all shares are being offered by the company. Shares fall 21%, to $2.25, in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 19, 2025 19:11 ET (23:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Five Below, ProAssurance, Akebia Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Five Below, ProAssurance, Akebia Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-20 07:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/FIVE\">Five Below</a> issued an upbeat outlook for its current fiscal year ahead as it posted a narrower-than-expected decline in comparable sales during its fiscal fourth quarter. The low-cost retailer's mid-2024 reset resulted in a better-than-expected end to the year, and momentum is expected to continue into its fiscal 2025. Same-store sales fell 3.0% in its recent quarter, better than the 3.3% decline expected by Wall Street. Shares rise 9.6%, to $82.88, in after-hours trading. \n</p>\n<p>\n  ProAssurance inked a roughly $1.3 billion deal to be bought by The Doctors Co. Under the agreement, ProAssurance's stockholders would receive $25 a share in cash, representing a roughly 60% premium to Wednesday's closing price. The deal is expected to close in the first half of 2026, pending approval by the specialty insurer's shareholders. Shares surge 51%, to $23.40, in post-market trading. \n</p>\n<p>\n  Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its common stock it expects to sell, nor did it disclose anticipated proceeds. It said all shares are being offered by the company. Shares fall 21%, to $2.25, in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 19, 2025 19:11 ET (23:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520115522","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520115522","pubTimestamp":1742425860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Five Below issued an upbeat outlook for its current fiscal year ahead as it posted a narrower-than-expected decline in comparable sales during its fiscal fourth quarter. The low-cost retailer's mid-2024 reset resulted in a better-than-expected end to the year, and momentum is expected to continue into its fiscal 2025. Same-store sales fell 3.0% in its recent quarter, better than the 3.3% decline expected by Wall Street. Shares rise 9.6%, to $82.88, in after-hours trading.ProAssurance inked a roughly $1.3 billion deal to be bought by The Doctors Co. Under the agreement, ProAssurance's stockholders would receive $25 a share in cash, representing a roughly 60% premium to Wednesday's closing price. The deal is expected to close in the first half of 2026, pending approval by the specialty insurer's shareholders. Shares surge 51%, to $23.40, in post-market trading.Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"值得关注的股票：以下五只、ProAssurance、Akebia Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1,"FIVE":1,"PRA":1},"content_text":"By Connor Hart \n\n\n \n\n\nFive Below issued an upbeat outlook for its current fiscal year ahead as it posted a narrower-than-expected decline in comparable sales during its fiscal fourth quarter. The low-cost retailer's mid-2024 reset resulted in a better-than-expected end to the year, and momentum is expected to continue into its fiscal 2025. Same-store sales fell 3.0% in its recent quarter, better than the 3.3% decline expected by Wall Street. Shares rise 9.6%, to $82.88, in after-hours trading. \n\n\n  ProAssurance inked a roughly $1.3 billion deal to be bought by The Doctors Co. Under the agreement, ProAssurance's stockholders would receive $25 a share in cash, representing a roughly 60% premium to Wednesday's closing price. The deal is expected to close in the first half of 2026, pending approval by the specialty insurer's shareholders. Shares surge 51%, to $23.40, in post-market trading. \n\n\n  Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its common stock it expects to sell, nor did it disclose anticipated proceeds. It said all shares are being offered by the company. Shares fall 21%, to $2.25, in after-hours trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2025 19:11 ET (23:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520115522"}